BACKGROUND:Postmenopausal women with breast cancer receivingaromatase inhibitors are at an increased risk of bone loss. The current study was undertaken to determine whether upfront versus delayed treatment with zoledronic acid (ZA) impacted bone loss. This report described the 5-year follow-up results. METHODS: A total of 551 postmenopausal women with breast cancer who completed tamoxifen treatment and were undergoing dailyletrozole treatment were randomized to either upfront (274 patients) or delayed (277 patients) ZA at a dose of 4 mg intravenously every 6 months. In the patients on the delayed treatment arm, ZA was initiated for a postbaseline bone mineral density T-score of <-2.0 or fracture. RESULTS: The incidence of a 5% decrease in the total lumbar spine bone mineral density at 5 years was 10.2% in the upfront treatment arm versus 41.2% in the delayed treatment arm (P<.0001). A total of 41 patients in the delayed treatment arm were eventually started on ZA. With the exception of increased NCI Common Toxicity Criteria (CTC) grade 1/2 elevated creatinine and fever in the patients treated on the upfront arm and cerebrovascular ischemia among those in the delayed treatment arm, there were no significant differences observed between arms with respect to the most common adverse events of arthralgia and back pain. Osteoporosis occurred less frequently in the upfront treatment arm (2 vs 8 cumulative cases), although this difference was not found to be statistically significant. Bone fractures occurred in 24 patients in the upfront treatment arm versus 25 patients in the delayed treatment arm. CONCLUSIONS: Immediate treatment with ZA prevented bone loss compared with delayed treatment in postmenopausal women receivingletrozole and these differences were maintained at 5 years. The incidence of osteoporosis or fractures was not found to be significantly different between treatment arms.
RCT Entities:
BACKGROUND: Postmenopausal women with breast cancer receiving aromatase inhibitors are at an increased risk of bone loss. The current study was undertaken to determine whether upfront versus delayed treatment with zoledronic acid (ZA) impacted bone loss. This report described the 5-year follow-up results. METHODS: A total of 551 postmenopausal women with breast cancer who completed tamoxifen treatment and were undergoing daily letrozole treatment were randomized to either upfront (274 patients) or delayed (277 patients) ZA at a dose of 4 mg intravenously every 6 months. In the patients on the delayed treatment arm, ZA was initiated for a postbaseline bone mineral density T-score of <-2.0 or fracture. RESULTS: The incidence of a 5% decrease in the total lumbar spine bone mineral density at 5 years was 10.2% in the upfront treatment arm versus 41.2% in the delayed treatment arm (P<.0001). A total of 41 patients in the delayed treatment arm were eventually started on ZA. With the exception of increased NCI Common Toxicity Criteria (CTC) grade 1/2 elevated creatinine and fever in the patients treated on the upfront arm and cerebrovascular ischemia among those in the delayed treatment arm, there were no significant differences observed between arms with respect to the most common adverse events of arthralgia and back pain. Osteoporosis occurred less frequently in the upfront treatment arm (2 vs 8 cumulative cases), although this difference was not found to be statistically significant. Bone fractures occurred in 24 patients in the upfront treatment arm versus 25 patients in the delayed treatment arm. CONCLUSIONS: Immediate treatment with ZA prevented bone loss compared with delayed treatment in postmenopausal women receiving letrozole and these differences were maintained at 5 years. The incidence of osteoporosis or fractures was not found to be significantly different between treatment arms.
Authors: Antonio Llombart; Antonio Frassoldati; Outi Paija; Harm Peter Sleeboom; Guy Jerusalem; Jeroen Mebis; Ines Deleu; Joel Miller; Nora Schenk; Patrick Neven Journal: Clin Breast Cancer Date: 2011-10-19 Impact factor: 3.225
Authors: Adam M Brufsky; W Graydon Harker; J Thaddeus Beck; Linda Bosserman; Charles Vogel; Christopher Seidler; Lixian Jin; Ghulam Warsi; Eliza Argonza-Aviles; John Hohneker; Solveig G Ericson; Edith A Perez Journal: Cancer Date: 2011-10-10 Impact factor: 6.860
Authors: Michael Gnant; Brigitte Mlineritsch; Herbert Stoeger; Gero Luschin-Ebengreuth; Dietmar Heck; Christian Menzel; Raimund Jakesz; Michael Seifert; Michael Hubalek; Gunda Pristauz; Thomas Bauernhofer; Holger Eidtmann; Wolfgang Eiermann; Guenther Steger; Werner Kwasny; Peter Dubsky; Gerhard Hochreiner; Ernst-Pius Forsthuber; Christian Fesl; Richard Greil Journal: Lancet Oncol Date: 2011-06-05 Impact factor: 41.316
Authors: Edith A Perez; Robert G Josse; Kathleen I Pritchard; James N Ingle; Silvana Martino; Brian P Findlay; Tamara N Shenkier; Richard G Tozer; Michael J Palmer; Lois E Shepherd; Shifang Liu; Dongsheng Tu; Paul E Goss Journal: J Clin Oncol Date: 2006-07-05 Impact factor: 44.544
Authors: Beat Thürlimann; Aparna Keshaviah; Alan S Coates; Henning Mouridsen; Louis Mauriac; John F Forbes; Robert Paridaens; Monica Castiglione-Gertsch; Richard D Gelber; Manuela Rabaglio; Ian Smith; Andrew Wardley; Andrew Wardly; Karen N Price; Aron Goldhirsch Journal: N Engl J Med Date: 2005-12-29 Impact factor: 91.245
Authors: Adam Brufsky; W Graydon Harker; J Thaddeus Beck; Robert Carroll; Elizabeth Tan-Chiu; Christopher Seidler; John Hohneker; Leo Lacerna; Stephanie Petrone; Edith A Perez Journal: J Clin Oncol Date: 2006-12-11 Impact factor: 44.544
Authors: R Coleman; R de Boer; H Eidtmann; A Llombart; N Davidson; P Neven; G von Minckwitz; H P Sleeboom; J Forbes; C Barrios; A Frassoldati; I Campbell; O Paija; N Martin; A Modi; N Bundred Journal: Ann Oncol Date: 2012-10-09 Impact factor: 32.976
Authors: Antonis Valachis; Nikolaos P Polyzos; Robert E Coleman; Michael Gnant; Holger Eidtmann; Adam M Brufsky; Rebecca Aft; Amye J Tevaarwerk; Karen Swenson; Pehr Lind; Davide Mauri Journal: Oncologist Date: 2013-02-12
Authors: John F Forbes; Jack Cuzick; Aman Buzdar; Anthony Howell; Jeffrey S Tobias; Michael Baum Journal: Lancet Oncol Date: 2008-01 Impact factor: 41.316
Authors: Robert E Coleman; Helen Marshall; David Cameron; David Dodwell; Roger Burkinshaw; Maccon Keane; Miguel Gil; Stephen J Houston; Robert J Grieve; Peter J Barrett-Lee; Diana Ritchie; Julia Pugh; Claire Gaunt; Una Rea; Jennifer Peterson; Claire Davies; Victoria Hiley; Walter Gregory; Richard Bell Journal: N Engl J Med Date: 2011-09-25 Impact factor: 91.245
Authors: F Vescini; R Attanasio; A Balestrieri; F Bandeira; S Bonadonna; V Camozzi; S Cassibba; R Cesareo; I Chiodini; C Maria Francucci; L Gianotti; F Grimaldi; R Guglielmi; B Madeo; C Marcocci; A Palermo; A Scillitani; E Vignali; V Rochira; M Zini Journal: J Endocrinol Invest Date: 2016-03-11 Impact factor: 4.256
Authors: Peyman Hadji; Matti S Aapro; Jean-Jacques Body; Michael Gnant; Maria Luisa Brandi; Jean Yves Reginster; M Carola Zillikens; Claus-C Glüer; Tobie de Villiers; Rod Baber; G David Roodman; Cyrus Cooper; Bente Langdahl; Santiago Palacios; John Kanis; Nasser Al-Daghri; Xavier Nogues; Erik Fink Eriksen; Andreas Kurth; Rene Rizzoli; Robert E Coleman Journal: J Bone Oncol Date: 2017-03-23 Impact factor: 4.072
Authors: Alessandro de Sire; Lorenzo Lippi; Konstantinos Venetis; Stefania Morganti; Elham Sajjadi; Claudio Curci; Antonio Ammendolia; Carmen Criscitiello; Nicola Fusco; Marco Invernizzi Journal: Front Oncol Date: 2022-01-21 Impact factor: 6.244